Comment on Cross-over to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy

The PLACE Trial randomized eyes with chronic central serous chorioretinopathy (CSCR) to either half-dose photodynamic therapy (HD-PDT) or high density subthreshold micropulse laser (HSML). The reported outcomes favored the HD-PDT group.1 More recently Van Rijssen and colleagues 2 conducted the REPLACE Trial where patients with persistent subretinal fluid exiting the PLACE trial were invited to participate. Those eyes that had failed HD-PDT were treated with HSML and those that had failed HSML were treated with HD-PDT.

Source: American Journal of Ophthalmology - November 10, 2020 Category: Opthalmology Authors: Lihteh Wu, Jos é A. Roca Tags: Correspondence Source Type: research